Aortic valve repair versus mechanical valve replacement for root aneurysm: the CAVIAAR multicentric study.


Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069

Informations de publication

Date de publication:
11 07 2022
Historique:
received: 30 09 2021
revised: 11 04 2022
accepted: 16 05 2022
pubmed: 19 5 2022
medline: 7 12 2022
entrez: 18 5 2022
Statut: ppublish

Résumé

Despite growing evidence that aortic valve repair improves long-term patient outcomes and quality of life, aortic valves are mostly replaced. We evaluate the effect of aortic valve repair versus replacement in patients with dystrophic aortic root aneurysm up to 4 years. The multicentric CAVIAAR (Conservation Aortique Valvulaire dans les Insuffisances Aortiques et les Anévrismes de la Racine aortique) prospective cohort study enrolled 261 patients: 130 underwent standardized aortic valve repair (REPAIR) consisting of remodelling root repair with expansible aortic ring annuloplasty, and 131 received mechanical composite valve and graft replacement (REPLACE). Primary outcome was a composite criterion of mortality, reoperation, thromboembolic or major bleeding events, endocarditis or operating site infections, pacemaker implantation and heart failure, analysed with propensity score-weighted Cox model analysis. Secondary outcomes included major adverse valve-related events and components of primary outcome. The mean age was 56.1 years, and valve was bicuspid in 115 patients (44.7%). Up to 4 years, REPAIR did not significantly differ from REPLACE in terms of primary outcome [Hazard Ratio (HR) 0.66 (0.39; 1.12)] but showed significantly less valve-related deaths (HR 0.09 [0.02; 0.34]) and major bleeding events (HR 0.37 [0.16; 0.85]) without an increased risk of valve-related reoperation (HR 2.10 [0.64; 6.96]). When accounting for the occurrence of multiple events in a single patient, the REPAIR group had half the occurrence of major adverse valve-related events (HR 0.51 [0.31; 0.86]). Although the primary outcome did not significantly differ between the REPAIR and REPLACE groups, the trend is in favour of REPAIR by a significant reduction of valve-related deaths and major bleeding events. Long-term follow-up beyond 4 years is needed to confirm these findings.

Identifiants

pubmed: 35583290
pii: 6588078
doi: 10.1093/ejcts/ezac283
pii:
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Auteurs

Emmanuel Lansac (E)

Department of Cardiac Surgery, CHU Pitié Salpetriere, Paris, France.

Isabelle Di Centa (I)

Department of Vascular Surgery, Hopital Foch, Suresnes, France.

Pichoy Danial (P)

Department of Cardiac Surgery, CHU Pitié Salpetriere, Paris, France.

Olivier Bouchot (O)

Department of Cardiac Surgery, CHU Le Bocage, Dijon, France.

Eric Arnaud-Crozat (E)

Department of Cardiac Surgery, CHU A. Michallon, La Tronche, France.

Rachid Hacini (R)

Department of Cardiac Surgery, CHU A. Michallon, La Tronche, France.

Fabien Doguet (F)

Department of Cardiac Surgery, C.H.U Charles Nicolle, Rouen, France.

Roland Demaria (R)

Department of Cardiac Surgery, CHU A. De Villeneuve, Montpellier, France.

Jean Philippe Verhoye (JP)

Department of Cardiac Surgery, CHU Pontchaillou, Rennes, France.

Jerome Jouan (J)

Department of Cardiac Surgery, CHU Limoges, France.

Didier Chatel (D)

Department of Cardiac Surgery, Clinique Saint Gatien, Tours, France.

Stephane Lopez (S)

Department of Cardiac Surgery, Institut Arnault Tzanck, Saint Laurent Du Var, France.

Thierry Folliguet (T)

Department of Cardiac Surgery, CHU Mondor, Créteil, France.

Pascal Leprince (P)

Department of Cardiac Surgery, CHU Pitié Salpetriere, Paris, France.

Thierry Langanay (T)

Department of Cardiac Surgery, CHU Pontchaillou, Rennes, France.

Christian Latremouille (C)

Department of Cardiac Surgery, CHU Hopital Europeen Georges Pompidou, Paris, France.

Georges Fayad (G)

Department of Cardiac Surgery, Centre Hospitalier Régional Universitaire de Lille, Lille, France.

Jean Philippe Fleury (JP)

Department of Cardiac Surgery, Clinique Belledone, Saint Martin d'Hères, France.

Jean Luc Monin (JL)

Department of Cardiac Surgery, Institut Mutualiste Montouris, Paris, France.

Leila Mankoubi (L)

Department of Cardiac Surgery, Institut Mutualiste Montouris, Paris, France.

Milena Noghin (M)

Department of Cardiac Surgery, Institut Mutualiste Montouris, Paris, France.

Alain Berrebi (A)

Department of Cardiac Surgery, Institut Mutualiste Montouris, Paris, France.

Sarah Pousset (S)

Department of Cardiac Surgery, Institut Mutualiste Montouris, Paris, France.

Aline Laubriet-Jazayeri (A)

Department of Cardiac Surgery, CHU Le Bocage, Dijon, France.

Alexandre Lafourcade (A)

AP-HP.Sorbonne Université, Hôpital Pitié Salpêtrière, Centre de Pharmacoépidémiologie (Cephepi), INSERM, CIC-1422, Paris, France.

Estelle Marcault (E)

APHP, Hôpital Bichat, Département d'Epidémiologie et Recherche Clinique, F-75018 Paris INSERM CIC-EC 1425, Paris, France.

Michel Kindo (M)

Department of Cardiac Surgery, CHU de Strasbourg, Strasbourg, France.

Laurent Payot (L)

Cardiology, Saint Brieuc Hospital, Saint Brieuc, France.

Eric Bergoend (E)

Department of Cardiac Surgery, CHU Mondor, Créteil, France.

Cecile Jourdain Hoffart (CJ)

APHP, Département de la Recherche Clinique et du Développement (DRCD) Groupement Interrégional de Recherche Clinique et d'Innovation-GIRCI Ile-de-France Hôpital Saint Louis, France.

Mathieu Debauchez (M)

Department of Cardiac Surgery, CHU Pitié Salpetriere, Paris, France.

Florence Tubach (F)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP.Sorbonne Université, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), CIC-1422, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH